Shilpa Medicare Limited shares surged by 3% in morning trade following a major announcement from the company. As of 9:18 AM, the shares were trading 3.83% higher at Rs 863.85.
The Central Drugs Standard Control Organization (CDSCO) has granted approval for Shilpa Medicare’s Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, indicated for the treatment of Non-alcoholic Fatty Liver Disease (NAFLD).
This approval is a significant milestone as it marks the first global authorization of NorUDCA for NAFLD treatment. NAFLD is a widespread liver condition, affecting approximately 25% of the global population, which translates to nearly 1.2 billion people worldwide. In India alone, around 188 million people are estimated to suffer from NAFLD.
If left untreated, NAFLD can advance to non-alcoholic steatohepatitis (NASH), causing severe liver damage and complications. NorUDCA is recognized for its choleretic and anti-inflammatory effects, which help improve bile flow, reduce liver inflammation, and potentially slow the progression of liver diseases related to NAFLD.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
